Abstract:Abstract Tumor-initiating cells (TICs) or so-called cancer stem cells (CSCs) are a minor subpopulation of poor differentiated cells that are responsible for tumor initiation, maintenance, and spreading. Hence, eliminating these cells is supposed to be an effective way of the treatment of cancer. By immunizing mice with TIC-enriched hepatocellular carcinoma (HCC) cells (Xu XL, et al. The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor. Carcinogensis. 2010; 31:167-74.) and by subsequent hybridoma technique, we have obtained an antibody 1B50-1, which recognizes the antigen of a 150 KD ion channel-composing protein. Despite the percentage of 1B50-1 positive cells varies from <1% to ∼90% in established hepatocellular carcinoma cell lines, the administration of this antibody by i.p. injection at a dose of 40mg/kg could suppress the growth of HCC cell lines’ engraftments in NOD/SCID mice with an inhibition rate that could be as high as 87%, comparing with control groups. Furthermore, 100 of 1B50-1 positive cells, but not the negative compartments, from several HCC cell lines were sufficient to initiate tumor growth in NOD/SCID mice, and displayed self-renewal ability as demonstrated by serial transplantation assay in mice. The 1B50-1 positive cells also expressed higher levels of Nanog, Sox-2, and Oct 4 than the negative ones. Immunohistochemical staining of 29 HCC specimen with 1B50-1 has revealed that only a small population of positive cells were scattered in 16 HCC tissues, and that these cells with similar distribution pattern were only found in 4 out of 12 paracancerous tissues. These data suggest that the antigen for 1B50-1 is a new marker for HCC tumor-initiating cells, and that it is a promising target for HCC molecular therapy. 1B50-1 is worthy of further developing into drug for the treatment of HCC. Funding: This study was supported by the National Basic Research Program of China (973 Program, No 2010CB529402), National Natural Science Foundation of China, and “863” Program (2008AA02Z108). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1666. doi:10.1158/1538-7445.AM2011-1666

1B50-1, a Mab Raised Against Recurrent Tumor Cells, Targets Liver Tumor-Initiating Cells by Binding to the Calcium Channel Α2δ1 Subunit

Targeting Tumor-Initiating Cells For The Treatment Of Hepatocellular Carcinoma

Effect of 1B50-1, a novel antibody, combined with chemotherapeutic drugs on proliferation of hepatocellular carcinoma cells

The Antitumor Activity Of Tcr-Mimic Antibody-Drug Conjugates (Tcrm-Adcs) Targeting The Intracellular Wilms Tumor 1 (Wt1) Oncoprotein

Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma

Effect of a Novel Inhibitory Mab Antibody Against Β-Subunit of F1F0 ATPase on HCC

Generation and Characterization of a Tetraspanin CD151/integrin Α6β1-Binding Domain Competitively Binding Monoclonal Antibody for Inhibition of Tumor Progression in HCC.

Development of Potent Antibody Drug Conjugates Against ICAM1+ Cancer Cells in Preclinical Models of Cholangiocarcinoma

Calcium channel α2δ1 subunit is a functional marker and therapeutic target for tumor-initiating cells in non-small cell lung cancer

Immunosuppressive Drug-Resistant Armored T-Cell Receptor T Cells for Immune Therapy of HCC in Liver Transplant Patients

Preparation And Application Of Anti-Hbx/Anti-Cd3 Bispecific Monoclonal Antibody (Bsab) Retargeting Effector Cells For Lysis Of Human Hepatoma Xenografts In Nude Mice

Production of anti-HBx/CD3 BSAB secreting hybrid-hybridomas and application of the BSAB retargeting effector cells for lysis of human HCC xenografts in nude mice

[Preparation of functional antibodies targeting tumor endothelia for the treatment of hepatic carcinoma].

Anti-cadherin-17 Antibody Modulates Beta-Catenin Signaling and Tumorigenicity of Hepatocellular Carcinoma.

Targeting CD44 variant 5 with an antibody-drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma

Targeting the Immune Privilege of Tumor-Initiating Cells to Enhance Cancer Immunotherapy

An Epcam/Cd3 Bispecific Antibody Efficiently Eliminates Hepatocellular Carcinoma Cells with Limited Galectin-1 Expression

Suppression of human hepatoma growth in vivo by a monoclonal antibody against a Mr 45,000 protein.

The CD39+ HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8+ T cells exhibit potent anti-HCC activity

Targeting CD44 Variant 5 by an Antibody‒Drug Conjugate As a Novel Therapeutic Regimen for Intrahepatic Cholangiocarcinoma

In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma